Previous 10 | Next 10 |
2023-08-31 17:58:28 ET Summary Takeda Pharmaceutical has recorded a 16.79% total return over the last 50 weeks, but risks are piling up, including loss of exclusivity and a sizable debt load. The advent of biosimilars for Takeda's major pharmaceuticals, Velcade and Vyvanse, will s...
2023-08-31 11:17:22 ET Summary Novo Nordisk is a high-quality pharmaceutical company with a unique ownership structure, controlled by a charitable foundation. The company specializes in diabetes and obesity treatments, with a focus on insulin and GLP-1 analogues. Despite a tem...
2023-08-29 13:45:03 ET Summary Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as ...
2023-08-28 07:12:00 ET More on ImmunoGen, Takeda, etc. ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ELAHERE Has Likely Blockbuster Potential ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential Takeda: Upside Ca...
2023-08-24 17:00:00 ET If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS) . Both companies offer attractive dividends, but which one is a better buy...
2023-08-23 14:22:14 ET Dividend stocks can be a port in the storm. Thanks to powerful wealth-building vehicles like dividend reinvestment plans, these stocks can take advantage of the power of both dollar-cost averaging and compounding. However, not all dividend stocks are great buys. Compa...
2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...
2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...
2023-07-31 09:00:00 ET Summary ASKA Pharmaceuticals' market cap is covered 30% by net non-operating assets that render its EV/EBITDA multiple too low for a growing generics business in Japan. It has a growing exposure to gynecological drugs, which in some cases are receiving benef...
2023-07-27 09:27:02 ET Takeda Pharmaceutical Company Limited (TAK) Q1 2023 Results Earnings Conference Call July 27, 2023, 06:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer An...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...